William Blair analyst Matt Phipps reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today. The company’s shares ...
$ 259.26 1.51 0.59% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback